Quantum-Si's Proteus Hits 19 Amino Acids, Targets All 20 by Year-End
QSI sits 78% above its 52-week low of $0.69.
Summary
Quantum-Si's Proteus platform now detects 19 amino acids, up from 18, and the company aims to demonstrate all 20 by year-end 2026. This follows the interim data presented at World HUPO 2026 showing a 30x improvement in sequencing alignments and 4.8x lower error rates. The milestone reduces technical risk ahead of the Q2 2027 commercial launch, which was delayed from earlier plans. The company is also deploying a development sequencing kit, moving the technology into routine testing. With a market cap around $267 million and a stock price near $1.23, this R&D progress is material for a company facing Nasdaq delisting and a 20% workforce reduction. The year-end target for all 20 amino acids is a near-term milestone that will validate the platform's readiness.
Updates
· SEC 8-K — Quantum-Si is deploying 19-amino-acid detection into a developmental sequencing kit for routine use on integrated Proteus instruments.
At the time of this announcement, QSI was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267M. The 52-week trading range was $0.69 to $3.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.